Cutaneous toxicities of new treatments for melanoma

Area of Science:

• Oncology
• Dermatology
• Pharmacology

Background:

• Advanced melanoma management has been revolutionized by targeted therapy and immunotherapy.
• These novel treatments, while effective, are associated with significant drug toxicities, particularly affecting the skin.
• Understanding and managing these cutaneous side effects is crucial for patient compliance and quality of life.

Purpose of the Study:

• To summarize the most common cutaneous side effects associated with BRAF inhibitors and immunotherapy for advanced melanoma.
• To provide consensus-based management strategies for these drug-induced skin toxicities.
• To explore the potential role of cutaneous toxicities as response markers in melanoma treatment.

Main Methods:

• Literature review and synthesis of current evidence on drug-induced skin toxicities in advanced melanoma.
• Analysis of common side effects reported for BRAF inhibitors (e.g., photosensitivity, keratosis, squamous cell carcinoma, new melanomas).
• Review of common side effects associated with immunotherapy (e.g., rash, pruritus, vitiligo) and their management.

Main Results:

• BRAF inhibitors commonly cause photosensitivity, plantar hyperkeratosis, verrucal keratosis, squamous cell carcinoma, and potential changes in nevi or new primary melanomas.
• Immunotherapy frequently leads to rash, pruritus, and vitiligo.
• The utility of these toxicities as predictive markers for treatment response remains under investigation.

Conclusions:

• Effective management of skin toxicities from BRAF inhibitors and immunotherapy is essential for maintaining treatment adherence and improving patient outcomes.
• Vigilance for specific dermatologic changes is required during treatment with these agents.
• Further research is needed to clarify the prognostic significance of treatment-related dermatologic adverse events.